134 related articles for article (PubMed ID: 37421603)
1. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
Zanwar S; Ho M; Lin Y; Kapoor P; Binder M; Buadi FK; Dispenzieri A; Dingli D; Fonder A; Gertz MA; Gonsalves W; Hayman SR; Hwa Y; Hobbs M; Kourelis T; Lacy MQ; Leung N; Muchtar E; Warsame R; Jevremovic D; Kyle RA; Rajkumar SV; Kumar S
Am J Hematol; 2023 Oct; 98(10):1540-1549. PubMed ID: 37421603
[TBL] [Abstract][Full Text] [Related]
2. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
3. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Tirumani SH; Sakellis C; Jacene H; Shinagare AB; Munshi NC; Ramaiya NH; Van den Abbeele AD
Clin Nucl Med; 2016 Jan; 41(1):e7-13. PubMed ID: 26252323
[TBL] [Abstract][Full Text] [Related]
4. Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades.
Bangolo AI; Fwelo P; Trivedi C; Sagireddy S; Aljanaahi H; Auda A; Mohamed M; Onyeka S; Fisher M; Thapa J; Tabucanon EJ; Georgiev L; Wishart A; Kumari S; Erikson C; Bangura M; Paddy O; Madhukar R; Gomez EL; Rathod J; Naria M; Hajal B; Awadhalla M; Siegel D; Parmar H; Biran N; Vesole DH; Phull P; Weissman S
World J Clin Oncol; 2023 Apr; 14(4):179-189. PubMed ID: 37124133
[TBL] [Abstract][Full Text] [Related]
5. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
6. Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma.
He J; Yue X; He D; Zhao Y; Yang Y; Zheng G; Zhang E; Han X; Wu W; Yang L; Chen J; Cai Z
Front Oncol; 2021; 11():668099. PubMed ID: 34307138
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R
Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.
Zhao Y; Zhou F
J Cancer Res Clin Oncol; 2023 Mar; 149(3):995-1006. PubMed ID: 35212816
[TBL] [Abstract][Full Text] [Related]
9. Research progress on treatment of extramedullary multiple myeloma.
Chen Y; Tao S; Zheng X; Shi Y; Zhang L; Chen K; He Z; Wang C; Yu L
Hematology; 2021 Dec; 26(1):985-994. PubMed ID: 34871523
[No Abstract] [Full Text] [Related]
10. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
Beksac M; Seval GC; Kanellias N; Coriu D; Rosiñol L; Ozet G; Goranova-Marinova V; Unal A; Bila J; Ozsan H; Ivanaj A; Balić LI; Kastritis E; Bladé J; Dimopoulos MA
Haematologica; 2020 Jan; 105(1):201-208. PubMed ID: 31278209
[TBL] [Abstract][Full Text] [Related]
11. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
12. How I treat extramedullary myeloma.
Touzeau C; Moreau P
Blood; 2016 Feb; 127(8):971-6. PubMed ID: 26679866
[TBL] [Abstract][Full Text] [Related]
13. Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures.
Dunphy K; Bazou D; Henry M; Meleady P; Miettinen JJ; Heckman CA; Dowling P; O'Gorman P
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568580
[TBL] [Abstract][Full Text] [Related]
14. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
15. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
16. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases.
Rasche L; Bernard C; Topp MS; Kapp M; Duell J; Wesemeier C; Haralambieva E; Maeder U; Einsele H; Knop S
Ann Hematol; 2012 Jul; 91(7):1031-7. PubMed ID: 22286070
[TBL] [Abstract][Full Text] [Related]
17. A prognostic model for patients with primary extramedullary multiple myeloma.
Zhang L; Chen S; Wang W; Wang Y; Liang Y
Front Cell Dev Biol; 2022; 10():1021587. PubMed ID: 36506092
[No Abstract] [Full Text] [Related]
18. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.
Farre L; Sanz G; Ruiz-Xivillé N; Castro de Moura M; Martin-Tejera JF; Gonçalves-Ribeiro S; Martinez-Iniesta M; Calaf M; Luis Mosquera J; Martín-Subero JI; Granada I; Esteller M; Domingo-Domenech E; Climent F; Villanueva A; Sureda A
Dis Model Mech; 2021 Jul; 14(7):. PubMed ID: 33988237
[TBL] [Abstract][Full Text] [Related]
20. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
